Johns Hopkins Institute for Clinical and Translational Research

约翰·霍普金斯临床与转化研究所

基本信息

批准号：
10398028
负责人：
Daniel Ernest Ford
金额：
$ 944.74万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-31 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10398028
关键词：
Accident and Emergency department Address Alzheimer&apos s Disease American Baltimore Budgets Clinic Clinical Research Collaborations Communication Communities Complex Conduct Clinical Trials Consultations Country Data Databases Diagnosis Disease Ecosystem Engineering Environment Funding Goals Health Health Promotion Health Status Health system Healthcare Healthcare Systems Home Hospitalization Hospitals Incentives Individual Informatics Information Systems Institutes Institution Insurance Interdisciplinary Study Intervention Joints Laboratories Lead Leadership Learning Maryland Measurable Medicare Mentors Methodology Mission Modeling Multiple Partners Obesity Outcome Pathway interactions Patients Pharmacy Schools Phase Population Population Group Population Heterogeneity Prevention Public Health Randomized Clinical Trials Research Research Personnel Research Support Research Training Resources Safety Science Scientist Services Sexually Transmitted Diseases Specialist Speed Substance abuse problem Technology Training Training Programs Translating Translational Research Translations Universities Vision Work care outcomes clinical infrastructure drug development drug discovery effective therapy experience global health health care availability health care delivery health disparity improved individual patient innovation investigator training multidisciplinary next generation novel therapeutics patient population population health precision medicine programs skills translational scientist waiver

项目摘要

Contact PD/PI: Ford, Daniel Ernest The Johns Hopkins Institute for Clinical and Translational Research (ICTR) has been a productive, innovative and impactful organization in transforming how clinical and translational research is conducted throughout Johns Hopkins University. Enhancing collaborative research teams, advancing informatics, promoting new methodologies, providing access to regulatory support, and bringing researchers and the community closer together as true partners in discovery have all made translational research more successful. Over the next five years, the Johns Hopkins ICTR will move beyond its current research community to create a comprehensive regional hub that includes new partners – the University of Maryland Baltimore (UMB), Morgan State University (MSU) and Kaiser Permanente Mid-Atlantic States (KPMAS). These partners bring complementary expertise and connections to distinct populations. Together, we have an opportunity to conduct high quality innovative research, and rapidly implement findings that impact the health of our state and region. Building on our extensive connections with community groups, we will move to a new phase of joint governance with bidirectional communication and participation on key ICTR committees. New programs will include a Trial Innovation Unit that will focus on improving methodologic and operational support for research teams conducting randomized clinical trials so that the impact of these trials is enhanced. A goal of this Unit will be to pilot and disseminate approaches that move randomized clinical trials closer to the precision medicine paradigm, with a focus on outcomes of greatest value to individual patients. Combining drug discovery scientists at Johns Hopkins with experts at the UMB School of Pharmacy, the ICTR will create a new Drug Discovery and Development Core. KPMAS and Johns Hopkins will continue to jointly fund programs that push the boundaries of how a Learning Health Care system can improve health outcomes. The ICTR provides a model for training investigators to work in multidisciplinary teams with experienced mentors using the most rigorous methodologies. We will enhance our training programs by incorporating principles of biodesign from the engineering tradition into the experience of all trainees. This places a higher emphasis on identification of the problem, engaging important stakeholders (clinicians, patients, IT professionals) to develop solutions, and identifying the most effective pathways to dissemination. Translational research demands the skills of many professionals working together to address complex problems. The Johns Hopkins ICTR is poised to leverage our current services to benefit new partners who have extensive responsibility for the conduct of research and health care delivery in Maryland. Working together, we expect to have a measurable impact on translational research in Maryland. Page 679 Project Summary/Abstract Contact PD/PI: Ford, Daniel Ernest By identifying and overcoming barriers in the translational pathway, increasing scientific collaboration, providing consultative services, clinical infrastructure, and technology cores that bridge the gap between the laboratory and the clinic, the ICTR helps to speed the pace of scientific discovery, bringing effective therapies to the public, and ultimately improving the health of Americans. Page 680

联系人 PD/PI：Ford、Daniel Ernest 约翰·霍普金斯大学临床与转化研究所 (ICTR) 一直是一个富有成效、富有创新精神的机构和有影响力的组织，改变整个临床和转化研究的进行方式约翰霍普金斯大学加强合作研究团队，推进信息学，促进新的发展。方法论，提供获得监管支持的机会，并拉近研究人员和社区的距离在接下来的五年里，作为发现领域真正的合作伙伴，我们共同努力使转化研究更加成功。多年来，约翰·霍普金斯大学卢旺达问题国际法庭将超越其当前的研究界，创建一个全面的区域中心，包括新合作伙伴——马里兰大学巴尔的摩分校 (UMB)、摩根州立大学 (MSU) 和 Kaiser Permanente Mid-Atlantic States (KPMAS) 这些合作伙伴带来了互补的专业知识。以及与不同人群的联系，我们有机会进行高质量的创新。研究，并快速实施影响我们州和地区健康的研究结果。与社区团体广泛联系，迈向共治新阶段卢旺达问题国际法庭关键委员会的双向沟通和参与新计划将包括审判。创新部门将专注于改善研究团队的方法和运营支持进行随机临床试验，以增强这些试验的影响。试点和传播使随机临床试验更接近精准医学的方法范式，重点关注对个体患者最有价值的结果，结合药物发现。约翰霍普金斯大学的科学家与 UMB 药学院的专家一起，卢旺达问题国际法庭将创造一种新药物发现与开发核心。KPMAS 和约翰霍普金斯大学将继续联合资助推动项目。卢旺达问题国际法庭提供了学习保健系统如何改善健康结果的界限。培训调查人员在多学科团队中工作的模型，该团队由经验丰富的导师使用最多我们将通过纳入生物设计原则来加强我们的培训计划。将工程传统融入所有学员的经验中，这更加强调识别。问题，让重要的利益相关者（临床医生、患者、IT 专业人员）参与制定解决方案，以及确定最有效的传播途径需要许多人的技能。约翰霍普金斯大学卢旺达问题国际法庭准备利用专家的力量共同解决复杂的问题。我们当前的服务有利于新合作伙伴，他们对开展研究和工作负有广泛责任我们希望通过共同努力，对马里兰州的医疗保健服务产生可衡量的影响。在马里兰州进行研究。第679页项目概要/摘要联系人 PD/PI：Ford、Daniel Ernest 通过识别和克服转化途径中的障碍，加强科学合作，提供咨询服务、临床基础设施和技术核心，以弥合两者之间的差距实验室和诊所，卢旺达问题国际法庭帮助加快科学发现的步伐，带来有效的治疗方法公众，并最终改善美国人的健康。第680页